Docetaxel Injection, Solution, Concentrate
Product Images NDC 57884-3041

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 57884-3041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jiangsu Hengrui Pharmaceuticals Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Doc07 0000 01)

Chemical structure of Docetaxel, showing the detailed molecular arrangement with multiple rings, hydroxyl groups, and side chains, consistent with the generic drug Docetaxel used in cancer treatment.*

FDA Label Image

Figure 1 (Doc07 0000 02)

A line graph depicting Disease-Free Survival (DFS) probability over time in months, comparing two treatment groups labeled TAC and FAC. The vertical axis shows DFS probability percentage, and the horizontal axis displays time from 0 to 66 months. The TAC group shows slightly higher survival probability throughout the timeline compared to the FAC group.*

FDA Label Image

Figure 2 (Doc07 0000 03)

A survival probability Kaplan-Meier curve chart depicting survival time in months on the x-axis and survival probability percentage on the y-axis. It compares two groups labeled TAC and FAC, showing survival trends over time up to 66 months.*

FDA Label Image

Figure 3 (Doc07 0000 04)

A Kaplan-Meier survival curve chart comparing overall survival probabilities over time in months for two groups labeled T75 and BSC. The solid line represents T75, and the dashed line represents BSC, with a log-rank p-value of 0.010 indicating statistical difference between groups.*

FDA Label Image

Figure 4 (Doc07 0000 05)

A Kaplan-Meier survival curve graph showing cumulative probability on the vertical axis and survival time in months on the horizontal axis. Two groups, labeled T75 and V/I, are compared, with a log-rank p-value of 0.13 indicating no statistically significant difference in overall survival.*

FDA Label Image

Figure 5 (Doc07 0000 06)

A survival probability chart plotting survival probability against survival time in months. The graph compares two groups, labeled T75 q3w and M q3w, showing their respective survival probabilities over a 30-month period.*

FDA Label Image

Figure 6 (Doc07 0000 07)

A line graph showing probability (%) on the y-axis versus time (months) on the x-axis for two groups labeled TCF and CF. The graph depicts survival or event probability decreasing over a 24-month period for both groups, with TCF generally showing higher probability values than CF.*

FDA Label Image

Figure 7 (Doc07 0000 08)

A survival probability chart depicting survival time in months on the x-axis and survival probability percentage on the y-axis. Two lines represent different groups labeled TCF and CF, showing their survival probabilities over a 36-month period.*

FDA Label Image

Figure 8 (Doc07 0000 09)

A Kaplan-Meier survival curve chart showing progression-free survival (PFS) probability over time in months. The chart compares two groups labeled TPF and PF, displaying PFS probability percentage on the vertical axis against progression-free survival time in months on the horizontal axis.*

FDA Label Image

Figure 9 (Doc07 0000 10)

A survival curve graph comparing survival probability percentages over time (months) for two treatment groups labeled TPF and PF. The vertical axis represents survival probability from 0% to 100%, and the horizontal axis shows survival time from 0 to 72 months. The TPF curve shows higher survival probabilities than the PF curve across the observed timeframe.*

FDA Label Image

Figure 10 (Doc07 0000 11)

A Kaplan-Meier survival probability graph comparing two groups, TPF (n=255) and PF (n=246), over survival time in months up to 72 months. The y-axis indicates survival probability percentage, and the x-axis shows time in months. The graph displays declining survival probabilities for both groups over time with separate curves for each group.*

FDA Label Image

20mg Vial Label (Doc07 0000 12)

Label for Docetaxel Injection USP 20 mg/mL in a 1 mL single-dose vial for intravenous infusion. The label specifies one-vial formulation and includes a caution for cytotoxicity, storage instructions between 2° to 25°C, and notes it is manufactured by Jiangsu Hengrui Pharmaceuticals Co., Ltd., China, and distributed by eVenus Pharmaceutical Laboratories, Inc., USA. It also notes the product is ready to add to infusion solution.*

FDA Label Image

80mg Vial Label (Doc07 0000 13)

The label for Docetaxel Injection USP shows an 80 mg/4 mL (20 mg/mL) concentration of docetaxel in an intravenous solution. It is a single-dose 4 mL vial, Rx only, and a one-vial formulation meant for intravenous infusion. The label includes dosing instructions, storage conditions (2 to 25°C), manufacturer details (Jiangsu Hengrui Pharmaceuticals Co., Ltd.), and a barcode.*

FDA Label Image

160mg Vial Label (Doc07 0000 14)

Label for Docetaxel Injection USP 160 mg/8 mL (20 mg/mL) intravenous injection solution, concentrate. Single-dose vial of 8 mL in one-vial formulation by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Instructions advise adding to infusion solution and note storage conditions and cytotoxic caution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.